Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
December 26, 2025
Respiratory 2025 Review: From Symptom Control to Disease Modification
December 26, 2025
Vaccines 2025 Review: From Emergency Platforms to Durable Public Health Assets
December 25, 2025
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
December 25, 2025
Cell and Gene Therapy 2025 Review: Acceleration, Accountability, and the Fight for Scalability
December 24, 2025
Neuroscience 2025 Review: Disease Modification Meets Deliverability
December 24, 2025
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
December 23, 2025
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
December 22, 2025
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
December 22, 2025